MX2020004375A - Imipridonas para gliomas. - Google Patents

Imipridonas para gliomas.

Info

Publication number
MX2020004375A
MX2020004375A MX2020004375A MX2020004375A MX2020004375A MX 2020004375 A MX2020004375 A MX 2020004375A MX 2020004375 A MX2020004375 A MX 2020004375A MX 2020004375 A MX2020004375 A MX 2020004375A MX 2020004375 A MX2020004375 A MX 2020004375A
Authority
MX
Mexico
Prior art keywords
imipridone
administration
imipridones
subject
methods
Prior art date
Application number
MX2020004375A
Other languages
English (en)
Inventor
Martin Stogniew
Joshua E Allen
Varun Vijay Prabhu
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of MX2020004375A publication Critical patent/MX2020004375A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las imipridonas modulan selectivamente receptores de Clase A acoplados a proteínas G (GPCR), tales como la subfamilia de receptores de dopamina tipo D2, y son útiles para tratar afecciones y trastornos que necesitan dicha modulación, tales como los cánceres. Específicamente, el cáncer involucra una estructura de la línea media del cerebro, un cáncer que tiene una mutación en histona H3, o ambos. Además, se proporcionan métodos para identificar si es probable que un sujeto que tiene estas afecciones, sea sensible a un régimen de tratamiento, tal como la administración de imipridona. Además, también se proporcionan métodos para evaluar la eficacia de un régimen de tratamiento, tal como la administración de imipridona, monitorizar o proporcionar un pronóstico para un sujeto con esta afección.
MX2020004375A 2017-11-03 2018-11-05 Imipridonas para gliomas. MX2020004375A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581478P 2017-11-03 2017-11-03
US15/947,840 US10172862B2 (en) 2017-01-30 2018-04-08 Imipridones for gliomas
PCT/US2018/059209 WO2019090222A1 (en) 2017-11-03 2018-11-05 Imipridones for gliomas

Publications (1)

Publication Number Publication Date
MX2020004375A true MX2020004375A (es) 2020-11-11

Family

ID=63038820

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004375A MX2020004375A (es) 2017-11-03 2018-11-05 Imipridonas para gliomas.
MX2023013341A MX2023013341A (es) 2017-11-03 2020-07-13 Imipridonas para gliomas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023013341A MX2023013341A (es) 2017-11-03 2020-07-13 Imipridonas para gliomas.

Country Status (15)

Country Link
US (5) US10172862B2 (es)
EP (1) EP3703681A4 (es)
JP (2) JP7319989B2 (es)
KR (2) KR102826312B1 (es)
CN (2) CN116173036A (es)
AU (2) AU2018360752A1 (es)
BR (1) BR112020008791A2 (es)
CA (1) CA3080815A1 (es)
EA (1) EA202090928A1 (es)
IL (1) IL274194A (es)
MA (1) MA50533A (es)
MX (2) MX2020004375A (es)
NZ (1) NZ764026A (es)
SG (1) SG11202003952YA (es)
WO (1) WO2019090222A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3408298T3 (pl) 2016-01-29 2025-03-31 Oncoceutics, Inc. Modulacja przez imiprydony receptora sprzężonego z białkiem g (gpcr)
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US20220143024A1 (en) * 2019-02-22 2022-05-12 Board Of Regents, The University Of Texas System Methods of using imipridones
MX2023001576A (es) 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem Síntesis de nuevos derivados de imipridona y su evaluación de su actividad anticáncerigena.
CN114957236B (zh) * 2021-02-25 2026-02-03 南京正大天晴制药有限公司 一种2-酰基氨基噻唑类化合物的制备方法
CN113248465B (zh) * 2021-06-16 2021-10-29 中国农业科学院北京畜牧兽医研究所 一种鹰嘴豆芽素a的合成方法
CN114632088B (zh) * 2022-05-16 2022-08-16 北京市神经外科研究所 阿糖胞苷化合物在制备治疗脊髓胶质瘤的药物中的用途
WO2024030645A1 (en) * 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
CN117731654B (zh) * 2024-02-18 2024-05-07 首都医科大学附属北京天坛医院 Jjh201601在初发性脑胶质瘤和复发性脑胶质瘤治疗中的新用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1638178A (en) * 1924-11-04 1927-08-09 Union Switch & Signal Co Railway-traffic-controlling apparatus
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
EP1644536A4 (en) 2003-07-08 2008-07-23 Univ California GENETIC MARKERS FOR RESPONSE TO ATYPIC ANTIPSYCHOTICS AND ANTIDEPRESSIVA AND METHOD FOR USE THEREOF
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
AU2008302345A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
US20130102477A1 (en) * 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US20130331381A1 (en) 2011-02-28 2013-12-12 Mcmaster University Treatment of Cancer WIth Dopamine Receptor Antagonists
FI4335511T3 (fi) 2011-04-29 2026-01-29 Penn State Res Found Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9688679B2 (en) * 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2014160130A1 (en) * 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
IL311202A (en) * 2013-11-15 2024-05-01 Oncoceutics Inc 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-A] pyrido[3,4-E] pyrimidine-5(1H)one, its salts and methods Use
LT3662910T (lt) 2014-03-31 2024-12-27 The Scripps Research Institute Trail geno indukcijai skirtas farmakoforas
WO2016123571A1 (en) * 2015-01-30 2016-08-04 Oncoceutics Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
PL3408298T3 (pl) * 2016-01-29 2025-03-31 Oncoceutics, Inc. Modulacja przez imiprydony receptora sprzężonego z białkiem g (gpcr)
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
KR20250102119A (ko) 2025-07-04
BR112020008791A2 (pt) 2020-10-20
EP3703681A4 (en) 2021-08-11
US10369154B2 (en) 2019-08-06
KR102826312B1 (ko) 2025-06-26
EP3703681A1 (en) 2020-09-09
CN116173036A (zh) 2023-05-30
WO2019090222A1 (en) 2019-05-09
EA202090928A1 (ru) 2020-08-14
KR20200117979A (ko) 2020-10-14
IL274194A (en) 2020-06-30
AU2018360752A1 (en) 2020-05-21
JP2021502417A (ja) 2021-01-28
US10946022B2 (en) 2021-03-16
US12102639B2 (en) 2024-10-01
US20210236499A1 (en) 2021-08-05
MX2023013341A (es) 2023-11-27
NZ764026A (en) 2025-12-19
US20240366613A1 (en) 2024-11-07
MA50533A (fr) 2020-09-09
US20200022982A1 (en) 2020-01-23
AU2024219839A1 (en) 2024-10-10
CA3080815A1 (en) 2019-05-09
JP2023139152A (ja) 2023-10-03
SG11202003952YA (en) 2020-05-28
US20180221375A1 (en) 2018-08-09
US10172862B2 (en) 2019-01-08
US20190183895A1 (en) 2019-06-20
JP7319989B2 (ja) 2023-08-02
CN111818919A (zh) 2020-10-23

Similar Documents

Publication Publication Date Title
MX2020004375A (es) Imipridonas para gliomas.
MX2018009227A (es) Modulacion del receptor acoplado a proteina g (gpcr) por imipridones.
CO2019011584A2 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos
MX2016006725A (es) Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
MX2017016863A (es) Metodo de tratamiento de tumores neuroendocrinos que sobreexpresan receptores de somatostatatina.
CL2019002108A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
GT201500317A (es) Composiciones y métodos para alterar la señalizacion del segundo mensajero
CR20150022A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno
HUE061847T2 (hu) Androgén receptor célzott degradálására alkalmas vegyületek és eljárások
CL2019002112A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX390517B (es) Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
HUE047699T2 (hu) Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
GT201700062A (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
MX2018004050A (es) Inhibidores marcados con 18f mejorados del antigeno prostatico especifico de membrana (psma) y su uso como agentes de formacion de imagenes para el cancer de prostata.
CR20140424A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
MX2017007707A (es) Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX2016015092A (es) Inhibidor de proliferacion de celulas madre cancerosas.
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
MX2015006538A (es) Marcadores de diagnostico para el tratamiento de trastornos proliferativos celulares con inhibidores de telomerasa.
UY36286A (es) Tratamientos médicos basados en anamorelina
IT201700061686A1 (it) Ruota premi seme